University of Washington Addictions, Drug, and Alcohol Institute
(UW ADAI)

The work group discussed two questions: was it possible to define “high THC” products, and were there gaps in requirements on cannabis product stability?

Public health and prevention interests expressed during a closed meeting with WSLCB leaders the previous day were top of mind for board members during the caucus.

In his final bill signing, Governor Jay Inslee offered hope Washington would continue to prosper under a supplemental budget with rates of cannabis spending largely the same as 2023.

The cannabis waste bill was lined up for Inslee’s signature, rules on THC legislation from 2023 were ready for review, and WSDA staff kept their eyes on the calendar for lab accreditation.

The first cannabis bill of 2024 was signed into law before a dynamic conclusion to the session as the “high THC” legislation criss-crossed the rotunda for a last minute change which may have fiscal consequences.

All cannabis bills were funded in the operating budget; the patient excise tax exemption bill was passed; a bill action was scheduled by the Governor; and lawmakers would conclude the 2024 regular session.

Senators made changes to data gathering requirements in a bill regulating “high THC” products before almost unanimously passing the measure and returning it to the House for concurrence.

The “high THC” legislation was expanded in scope before passage in the Senate and the cannabis waste bill was passed in the House ahead of the deadline on Friday which three cannabis bills still had to make.

Interest in advancing inactive legislation via budget proviso had been activated, the “high THC” bill was positioned for floor activity in the Senate, and floor sessions would continue in the push to sine die.

Senators decided the “high THC” bill was similar enough to a companion to skip a public hearing; all testimony on the bill to exempt patients from cannabis excise taxes was supportive.